Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggar R, Steen VD, Strek ME, Bernstein EJ, Bhatt N, Castelino FV, Chung L, Domsic RT, Flaherty KR, Gupta N, Kahaleh B, Martinez FJ, Morrow LE, Moua T, Patel N, Shlobin OA, Southern BD, Volkmann ER, Khanna D. Rahaghi FF, et al. Among authors: hsu vm. Respir Res. 2023 Jan 9;24(1):6. doi: 10.1186/s12931-022-02292-3. Respir Res. 2023. PMID: 36624431 Free PMC article.
Cyclophosphamide versus placebo in scleroderma lung disease.
Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Tashkin DP, et al. Among authors: hsu vm. N Engl J Med. 2006 Jun 22;354(25):2655-66. doi: 10.1056/NEJMoa055120. N Engl J Med. 2006. PMID: 16790698 Free article. Clinical Trial.
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen Fv, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR; Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Denton CP, et al. Among authors: hsu vm. Arthritis Rheum. 2007 Jan;56(1):323-33. doi: 10.1002/art.22289. Arthritis Rheum. 2007. PMID: 17195236 Free article. Clinical Trial.
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ; Scleroderma Lung Study Group. Khanna D, et al. Among authors: hsu vm. Arthritis Rheum. 2007 May;56(5):1676-84. doi: 10.1002/art.22580. Arthritis Rheum. 2007. PMID: 17469162 Free article. Clinical Trial.
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, Goldin J, Arriola E, Strange C, Bolster MB, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Khanna D, Li N, Li G; Scleroderma Lung Study Research Group. Tashkin DP, et al. Among authors: hsu vm. Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026-34. doi: 10.1164/rccm.200702-326OC. Epub 2007 Aug 23. Am J Respir Crit Care Med. 2007. PMID: 17717203 Free PMC article. Clinical Trial.
Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial.
Merkel PA, Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH; CAT-192 Research Group; Scleroderma Clinical Trials Consortium. Merkel PA, et al. Among authors: hsu vm. Arthritis Rheum. 2008 May 15;59(5):699-705. doi: 10.1002/art.23564. Arthritis Rheum. 2008. PMID: 18438905 Free PMC article. Clinical Trial.
Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis.
Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibold JR, Furst DE; EPOSS-Omeract Group. Distler O, et al. Arthritis Rheum. 2008 Jun 15;59(6):867-75. doi: 10.1002/art.23718. Arthritis Rheum. 2008. PMID: 18512721 Free article.
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM. Chung L, et al. Arthritis Rheum. 2009 Mar;60(3):870-7. doi: 10.1002/art.24351. Arthritis Rheum. 2009. PMID: 19248104 Free article. Clinical Trial.
110 results